ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity.

ABSTRACT:

Purpose

Tumor heterogeneity complicates patient treatment and can be due to transitioning of cancer cells across phenotypic cell states. This process is associated with the acquisition of independence from an oncogenic driver, such as the estrogen receptor (ER) in breast cancer (BC), resulting in tumor progression, therapeutic failure and metastatic spread. The transcription factor ONECUT2 (OC2) has been shown to be a master regulator protein of metastatic castration-resistant prostate cancer (mCRPC) tumors that promotes lineage plasticity to a drug-resistant neuroendocrine (NEPC) phenotype. Here, we investigate the role of OC2 in the dynamic conversion between different molecular subtypes in BC.

Methods

We analyze OC2 expression and clinical significance in BC using public

SUBMITTER: Zamora I 

PROVIDER: S-EPMC11850477 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature